CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Västra Hamnen Corporate Finance, in its initial analysis of the Company, values CombiGene at SEK 12.19 per share.

The analysis is the first one that Västra Hamnen has carried out of CombiGene since the collaboration began in April 2024. It is based on a risk-adjusted DCF model, which indicates a fair value. The analysis is published on Västra Hamnen's website and available here.

“Västra Hamnen's analysis highlights the potential that exists in our projects, which are aimed at large patient groups where effective and sustainable treatments are currently lacking. As our work progresses towards the set milestones, the risk in the projects decreases, which positively affects the valuation,” comments CombiGene's CEO Peter Ekolind.

Contacts

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Sign up here to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at combigene.com.

Attachments

Västra Hamnen publishes initial analysis of CombiGene

© Modular Finance, source Nordic Press Releases